Vaccinex (VCNX) Stock Price, News & Analysis

Company Overview

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Key Stats

• Today's Range: $0.52 to $0.60
• 50-Day Range: $0.52 to $1.29
• 52-Week Range: $0.28 to $8.90
• Volume: 4,332 shs
• Average Volume: 57,184 shs
• Market Capitalization: $1.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VCNX Stock Analysis - Frequently Asked Questions

How have VCNX shares performed this year?

Vaccinex's stock was trading at $0.98 at the start of the year. Since then, VCNX shares have decreased by 46.6% and is now trading at $0.5236.
View the best growth stocks for 2025 here.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) posted its earnings results on Monday, November, 8th. The company reported ($35.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($60.90) by $25.20. The company had revenue of $0.05 million for the quarter.

When did Vaccinex's stock split?

Vaccinex's stock reverse split before market open on Tuesday, February 20th 2024. The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Vaccinex IPO?

Vaccinex (VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), Vaxart (VXRT), NIO (NIO) and SNDL (SNDL).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 4/04/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VCNX
• CIK: 1205922
• Web: www.vaccinex.com
• Phone: (585) 271-2700
• Fax: 585-271-2765
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($48.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-20,250,000.00
• Net Margins: N/A
• Pretax Margin: -4,787.89%
• Return on Equity: N/A
• Return on Assets: -383.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: $388,000.00
• Price / Sales: 3.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.59) per share
• Price / Book: -0.20

Miscellaneous

• Outstanding Shares: 2,600,000
• Free Float: 1,261,000
• Market Cap: $1.36 million
• Optionable: No Data
• Beta: 1.10